Compare MPV & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | QNCX |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 167.0M |
| IPO Year | N/A | 2019 |
| Metric | MPV | QNCX |
|---|---|---|
| Price | $19.08 | $0.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 9.5K | ★ 67.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.22 | $0.09 |
| 52 Week High | $21.00 | $4.55 |
| Indicator | MPV | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 27.94 |
| Support Level | $18.64 | $0.09 |
| Resistance Level | $19.54 | $0.98 |
| Average True Range (ATR) | 0.34 | 0.02 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 78.95 | 21.43 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.